Welcome to our dedicated page for Hookipa Pharma news (Ticker: HOOK), a resource for investors and traders seeking the latest updates and insights on Hookipa Pharma stock.
HOOKIPA Pharma Inc. (NASDAQ: HOOK) is a clinical-stage biopharmaceutical company pioneering arenavirus-based immunotherapies for cancer and infectious diseases. This page aggregates official announcements, including clinical trial updates, regulatory milestones, and strategic partnerships, providing investors and researchers a centralized resource for tracking the company’s progress.
Users will find timely updates on HOOKIPA’s Vaxwave® and Therat® platforms, which leverage viral vector technology to stimulate durable immune responses. Key content includes trial results for HPV16+ head and neck cancer therapies, hepatitis B/HIV collaboration updates, and financial disclosures. The platform’s stakeholders to monitor developments in immunotherapy approaches designed to overcome traditional treatment limitations.
Bookmark this page for direct access to press releases, SEC filings, and event transcripts. Check regularly for updates on HOOKIPA’s pipeline advancements and industry collaborations that shape its position in the immuno-oncology landscape.
HOOKIPA Pharma (NASDAQ: HOOK) has appointed Tim Reilly, Ph.D., to its Board of Directors, effective immediately. Reilly, a veteran in product development and early clinical trials, will enhance HOOKIPA's oncology initiatives, including the Phase 2 HB-200 program for head and neck cancer and preparations for the HB-300 prostate cancer program. His extensive experience includes 18 years at Bristol Myers Squibb, contributing to 12 therapy approvals. HOOKIPA focuses on innovative immunotherapies utilizing its proprietary arenavirus platform to target various cancers.
HOOKIPA Pharma announced positive preclinical data showcasing potent T cell responses and tumor control against cancer using its arenaviral platform. The results, presented at the AACR Annual Meeting, demonstrate effective combination strategies with 4-1BB agonists and adoptive T cell transfers. The company is preparing to file an IND for its HB-300 program targeting prostate cancer. Biomarker data from the ongoing HB-200 study in HPV16+ head and neck cancers indicate a significant induction of tumor antigen-specific T cell responses, further validating the potential of HOOKIPA's innovative immunotherapies.
HOOKIPA Pharma, a clinical-stage biopharmaceutical company, announced participation in investor meetings at the Kempen Life Sciences Conference in Amsterdam on April 20-21, 2022. The company focuses on developing immunotherapies using its proprietary arenavirus platform, targeting various cancers, including HPV16+ and KRAS-mutated cancers. HOOKIPA aims to advance novel treatments that enhance T cell responses and is also working on functional cures for HBV and HIV in collaboration with Gilead.
HOOKIPA Pharma reported significant advancements in its oncology pipeline, notably with HB-200, which showed a 75% disease control rate in heavily pre-treated head and neck cancer patients. The candidate received FDA Fast Track designation and has advanced to a Phase 2 trial alongside pembrolizumab. Additionally, a collaboration with Gilead triggered a $54 million commitment. HOOKIPA ended 2021 with a pro forma cash position of $156.9 million. Despite a revenue decrease to $18.4 million in 2021 and a net loss of $75.7 million, the company projects funding into H1 2024, supporting ongoing and new programs.
HOOKIPA Pharma Inc. (NASDAQ: HOOK) announced the promotion of Klaus Orlinger, Ph.D. to Chief Scientific Officer. Since joining in 2012, Orlinger has significantly contributed to the development of HOOKIPA’s arenavirus platform, enhancing its clinical potential in treating infectious diseases and cancers. CEO Joern Aldag highlighted his expertise and leadership role in advancing the company's immunotherapy initiatives. HOOKIPA continues to develop novel treatments targeting various cancers and aims for functional cures for HBV and HIV in collaboration with Gilead.
HOOKIPA Pharma Inc. (NASDAQ: HOOK) announced it will release its fourth quarter and full year 2021 financial results on March 24, 2022, before market opening. A live conference call and webcast will take place at 8:30 AM ET to discuss these results and provide updates on corporate developments. HOOKIPA focuses on developing novel immunotherapies utilizing its proprietary arenavirus platform, targeting serious diseases including HPV16+ cancers and collaborating with Gilead on HBV and HIV functional cures.
HOOKIPA Pharma Inc. (NASDAQ: HOOK) announced four poster presentations at the 2022 AACR Annual Meeting, showcasing significant preclinical and clinical data on its arenaviral immunotherapy platform. The research emphasizes strong T cell responses, potential drug combinations, and highlights HB-201 and HB-202's efficacy in treating HPV16+ head and neck cancers. The presented abstracts focus on the broad potential of arenaviral vectors in cancer therapy, indicating their capability to activate tumor-specific CD8+ T cells. HOOKIPA's innovative approach aims to enhance cancer treatment outcomes across various malignancies.
HOOKIPA Pharma Inc. (Nasdaq: HOOK) has announced a public offering of 21.7 million shares of common stock priced at $2.00 each and 15,800 shares of non-voting Series A-1 preferred stock at $2,000 each. The total expected proceeds from this offering are approximately $75 million before expenses. The offering is set to close on March 4, 2022, subject to customary conditions, and underwriters have a 30-day option to purchase an additional 5.625 million shares. Proceeds will support HOOKIPA's immunotherapy development pipeline targeting various cancers and diseases.
HOOKIPA Pharma Inc. (Nasdaq: HOOK) announced plans for an underwritten public offering of its common stock and non-voting Series A convertible preferred stock. The offering allows underwriters a 30-day option to buy up to 15% more shares. The offering is subject to market conditions, and terms may vary. Securities offered are under a shelf registration statement, with details to be filed with the SEC. HOOKIPA focuses on immunotherapeutics for severe diseases, including cancer and viral infections.
HOOKIPA Pharma has announced an amended collaboration with Gilead to develop an arenaviral-based therapy for HIV, progressing through a Phase 1b clinical trial. Gilead is providing financial support, including a $15 million initiation fee and a potential $35 million in equity financing. The partnership aims to enhance Gilead's research in functional cures for HIV and HBV. HOOKIPA previously received a $4 million milestone payment and will receive an additional $5 million equity investment. The agreement underscores HOOKIPA’s innovative platform for immunotherapies targeting significant viral diseases.
